1. Home
  2. CLLS vs PFO Comparison

CLLS vs PFO Comparison

Compare CLLS & PFO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cellectis S.A.

CLLS

Cellectis S.A.

SELL

Current Price

$0.97

Market Cap

103.8M

Sector

Health Care

ML Signal

SELL

Logo Flaherty & Crumrine Preferred and Income Opportunity Fund Incorporated

PFO

Flaherty & Crumrine Preferred and Income Opportunity Fund Incorporated

SELL

Current Price

$8.30

Market Cap

110.8M

Sector

Finance

ML Signal

SELL

Company Overview

Basic Information
Metric
CLLS
PFO
Founded
1999
1991
Country
France
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance Companies
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
103.8M
110.8M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
CLLS
PFO
Price
$0.97
$8.30
Analyst Decision
Buy
Analyst Count
5
0
Target Price
★ $4.45
N/A
AVG Volume (30 Days)
★ 55.6K
24.3K
Earning Date
11-12-2026
01-01-0001
Dividend Yield
N/A
★ 6.51%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.88
$8.32
52 Week High
$5.45
$9.73

Technical Indicators

Market Signals
Indicator
CLLS
PFO
Relative Strength Index (RSI) 37.12 36.25
Support Level N/A N/A
Resistance Level $1.28 $9.24
Average True Range (ATR) 0.12 0.13
MACD 0.00 -0.02
Stochastic Oscillator 0.00 20.37

Price Performance

Historical Comparison
CLLS
PFO

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

About PFO Flaherty & Crumrine Preferred and Income Opportunity Fund Incorporated

Flaherty & Crumrine Prfd Income Oppo is the United States-based diversified, closed-end management investment company. Its primary investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.

Share on Social Networks: